Table 4.
Compounds ID | Structure | scPTZb | CLogP | Predicted |
|||
---|---|---|---|---|---|---|---|
CoMSIA | CoMFA | ||||||
CLogP | Residual | CLogP | Residual | ||||
JF 102
ADD a 275006 |
1 | 2.42 | 1.82 | 0.6 | 2.09 | 0.33 | |
E 123
ADD 206043 |
2 | 2.78 | 2.55 | 0.23 | 2.53 | 0.25 | |
E 121
ADD 206041 |
1 | 3.35 | 3.02 | 0.33 | 3.15 | 0.20 | |
JF 37
ADD 261108 |
1 | 0.97 | 1.23 | −0.26 | 0.949 | 0.021 | |
JF 93
ADD 273008 |
1 | 1.97 | 1.84 | 0.13 | 2.06 | −0.09 | |
JF 43
ADD 261110 |
1 | 2.01 | 1.97 | 0.04 | 1.97 | 0.04 |
ADD, Antiepileptic Drug Development;
Phase 1 in mice activity – class 1 = activity at 100 mg/kg or <; class 2 = activity between 100 and 300 mg/kg